Cabozantinib/atezolizumab does not improve PFS or OS in advanced RCC
“The addition of atezolizumab to cabozantinib did not result in improved clinical outcomes in patients with mRCC who progressed on or after prior ICI treatment,” said Toni K. Choueiri, MD.
Darolutamide in extended duration shows safety and efficacy for nonmetastatic CRPC
“The ARAMIS Rollover Study extended the duration of darolutamide treatment and demonstrated the long-term safety of darolutamide in patients with [nonmetastatic CRPC],” said Neal D. Shore, MD.
CAR T-cell therapy shows promise in renal cell carcinoma
Results from the phase 1 TRAVERSE trial showed signals of anti-tumor activity with the CAR T-cell therapy ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.
Clear cell RCC imaging agent 89Zr-DFO-girentuximab demonstrates accuracy
“I clearly think that this agent improves the identification of clear cell kidney cancer compared with any metric on any cross-sectional imaging study to date," says Brian M. Shuch, MD.
Enzalutamide/ADT survival benefit in mHSPC unaffected by prior local therapy
The findings came from a post-hoc analysis of the phase 3 ARCHES trial.
Avelumab maintenance benefit in urothelial carcinoma sustained with extended follow-up
Long-term data from the phase 3 JAVELIN Bladder 100 trial continued to show an overall survival (OS) boost with frontline avelumab maintenance in patients with metastatic urothelial cancer.
Olaparib addition to abiraterone delays progression in frontline mCRPC
The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to abiraterone acetate in the frontline setting significantly improved radiographic progression-free survival versus placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer.
Impressive disease-free survival seen with adjuvant pembrolizumab in clear cell RCC
“Although numbers of participants with certain disease risk features were small, the DFS benefit was consistent across subgroups,” said lead study author Toni K. Choueiri, MD.
Study offers clues on optimal patients for immunotherapy in prostate cancer
Men whose tumors are microsatellite instability–high or mismatch repair–deficient may have a greater response to immune checkpoint blockade compared with patients with high tumor mutational burden.
Combination treatment with durvalumab/vicineum elicits complete responses in high-grade NMIBC
“The combination of Vicineum and durvalumab in BCG-unresponsive NMIBC is tolerated well and no new safety signals were identified; the doublet has a similar safety profile to [what is seen with] both agents used individually,” says Sandeep Gurram, MD.
Posthoc data show depth of frontline avelumab maintenance OS benefit in bladder cancer
Avelumab is approved by the FDA for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Adjuvant pembrolizumab delays disease recurrence in renal cell carcinoma
Findings from the phase 3 KEYNOTE-564 trial showed that adjuvant pembrolizumab significantly improved disease-free survival versus placebo in patients with clear cell renal cell carcinoma.
OS benefit with frontline avelumab maintenance in urothelial cancer sustained in Japanese subgroup
The subgroup analysis assessed data from the pivotal phase 3 JAVELIN Bladder 100 trial showed.
Cabozantinib hits high intracranial response rate in metastatic kidney cancer
The multikinase inhibitor showed significant intracranial and extracranial responses in patients with metastatic renal cell carcinoma and brain metastases.
Avelumab frontline maintenance benefit sustained across subgroups in bladder cancer
An analysis from the pivotal phase 3 JAVELIN Bladder 100 trial showed that the survival benefit observed with frontline maintenance avelumab in the overall population was sustained across several prespecified patients subgroups.
Nivolumab/cabozantinib combo impresses as frontline kidney cancer treatment
The combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.
Ipatasertib/abiraterone regimen delays progression in mCRPC with PTEN loss
The addition of the AKT inhibitor ipatasertib to abiraterone acetate and prednisone improved radiographic progression-free survival, with overall survival data still eagerly anticipated.
2 Clarke Drive Cranbury, NJ 08512